Last reviewed · How we verify
Diampromid (DIAMPROMIDE)
Diampromid (generic name: DIAMPROMIDE) is a drug. It is currently in Phase 2 development.
Diampromide is a small molecule that works by interacting with a specific target in the body to produce a therapeutic effect.
Diampromide is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known whether it is FDA approved or off-patent. The approved indications for Diampromide are also unknown. As a result, key safety considerations and generic manufacturers are also not available. Further research is needed to understand the properties and uses of Diampromide.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DIAMPROMIDE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine Diampromide as a key that fits into a lock in the body. When it binds to its target, it helps to turn off or on certain cellular processes that are involved in the disease it's meant to treat. This can help to restore balance and reduce symptoms.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diampromid CI brief — competitive landscape report
- Diampromid updates RSS · CI watch RSS
Frequently asked questions about Diampromid
What is Diampromid?
How does Diampromid work?
What is the generic name of Diampromid?
What development phase is Diampromid in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing